Methods for enhancing antibody-induced cell lysis and treating cancer
CA 2410371 C · Owner: Coley Pharmaceutical Gmbh · Inventors: Hartmann, Gunther; Weiner, George
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to methods and products for treating cancer. In particular the invention relates to combinations of nucleic acids and antibodies for the , treatment and prevention of cancer. The invention also relates to diagnostic methods , for screening cancer cells. In one embodiment the invention relates to the , use of an immunostimulatory nucleic acid comprising at least one unmethylated CpG dinucleotide and an antibody specific for CD19 CD20, CD22 or CD40 antigen in , the , treatment or prevention of a B cell malignancy wherein the immunostimulatory , nucleic acid upregulates expression of the antigen.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 22, 2001 and granted November 17, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 22, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 22, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.